AXSM Overview
Upcoming Projects (AXSM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AXSM)
-
Discussing the commercial potential for AXS-05 in Major Depressive Disorder
Ticker: AXSM
Executed On: Sep 28, 2020 at 02:00 PM EDT -
A Second View: Examining the Depression Drug Development Landscape including SAGE-217, AXS-05, Rel-1017, and esketamine
Tickers: SAGE, AXSM, JNJ, RLMD
Executed On: Apr 14, 2020 at 11:00 AM EDT -
Examining the Depression Drug Development Landscape including SAGE-217, AXS-05, Rel-1017, and esketamine
Tickers: SAGE, AXSM, JNJ, RLMD
Executed On: Apr 10, 2020 at 03:00 PM EDT
Upcoming & Overdue Catalysts (AXSM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AXSM)
-
Axsome Therapeutics (AXSM) Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 in the Acute Treatment of Migraine
Ticker: AXSM
Occurred on: Sep 24, 2020 -
Axsome's (AXSM) AXS-05 Data Results from GEMINI Phase 3 Trial in Major Depressive Disorder
Ticker: AXSM
Occurred on: Dec 16, 2019 -
AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
Ticker: AXSM
Occurred on: Jan 09, 2018 -
Phase 3 trial of AXS-02 for Complex regional pain syndrome (CRPS) expected to be completed by end of 2017 - Discontinued
Ticker: AXSM
Occurred on: Jan 09, 2018 -
Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
Ticker: AXSM
Occurred on: Mar 17, 2016
Strategic Initiatives (AXSM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
